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Nineteen-ninety was a significant year for clinical islet transplantation, since after 
many attempts reports of short terml and prolonged2.6 insulin independence following 
human islet allotransplantation, indicated that it is possible to replace the endocrine 
function of the pancreas by an islet transplant in man. The development of improved 
procedures for islet isolation and purification from large animals7. 11 and humanl2.16 
pancreata have resulted in significant progress in both the number and purity of islets that 
can be obtained from each pancreas. In addition, the use of more powerful immunosup-
pressive agents such as cyclosporine A 1.3.16 or FK5062,6 resulted in prolonged human islet 
allograft survival in some cases. This report summarized our initial experience on islet 
isolation and intrahepatic allotransplantation. 
MATERIALS AND METHODS 
PATIENTS 
Twenty-five intrahepatic islet allografts were performed in 24 patients between 
January 10, 1990 and May 4, 1991.6 
Group 1. Ten patients aged 8-58 years underwent combined liver-islet 
allotransplantation following upper-abdominal exenteration for tumors too extensive to 
be removed with less drastic procedures.17•18 More detailed results on nine of these 
patients have been reported previously.2.6 Liver, pancreas, spleen, stomach, duodenum, 
proximal jejunum, terminal ileum, ascending and transverse colon (three cases), and part 
of the right atrium (one case) was removed. A cadaveric orthotopic liver allograft was 
donel8 and the graft portal vein was anastomosed to the recipient superior mesenteric 
vein. Arterialization was from the recipient aorta or celiac axis. A 14 g catheter with a 
heparin lock was placed in a superior mesenteric vein.2 Bowel continuity was reestab-
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lished and biliary drainage was via a chole-
docojejunostomy. 
Group 2. Two patients had near total 
pancreatectomy for pain relief due to chronic 
pancreatitis and received an autograft of islets 
obtained from the excised pancreas. 
Group 3. Three type I diabetic patients aged 
22-56 years received a combined liver-islet al-
lograft. The indications for liver transplantation 
were cirrhosis secondary to hepatitis C, alcoholic 
cirrhosis and cryptogenic cirrhosis. 
Group 4. Nine patients aged 28-42 years 
received 10 combined cadaveric kidney-islet grafts 
(one retransplant) for end-stage renal disease 
secondary to type I diabetes mellitus. Immedi-
ately after renal transplantation, an upper mid-
line incision was performed and a 16-18 gcatheter 
was placed in a jejunal vein for islet infusion. All 
patients had negative C-peptide in response to a 
Sustacal challenge test performed before islet 
transplantation. 
ORGAN PROCUREMENT 
The cadaveric donor ABO types were the 
same as, or compatible with the recipient ABO 
types. HLA matching was random and the anti-
gen match was zero to three. There were two 
positive cytotoxic crossmatches in Group 1 (Clus-
ter-Islet) and twO in Group 3 (Liver-Islet). The 
livers, kidneys and pancreata were obtained from 
multi-organ donors. 17 •2o In situ perfusion of the 
abdominal aorta was with 1500-2000 ml of 
University of Wisconsin solution (UWS). An 
additional 500-1000 ml of UWS were infused 
directly into the liver via the portal vein, which 
was encircled below the catheter tip to prevent 
retrograde leakage. Venous hypertension of the 
pancreas was avoided by venting the portal and/ 
or splenic vein. The specimens were immersed in 
UWS and packed on ice. The pancreas of the liver 
or kidney donor was the source of the primary 
islet graft for all patients except one patient in 
Group 1 and one patient in Group 4 who received 
islets from a third party pancreas donor. Four 
patients in Group 1 and three patients in Group 
4 were given islets from 1-2 additional donors 1-
7 days after the principal operation. One patient 
in Group 4 was retransplanted (Kidney-Islet) 
seven months after the first combined graft be-
cause of irreversible kidney rejection. 
ISLET PREPARATION AND ADMINISTRATION 
Cold ischemia time of the 28 pancreata 
averaged 7.5 hours (range 4-12) with no statisti-
cally significant difference berween groups. The 
human islets were obtained by a modification 10 of 
the automated method for human islet isolation 13 
that is described in details in a previous chapter 
of this book. Briefly, after cannulation of the 
pancreatic duct 350 ml of Hanks solution con-
taining 2 mg/ml collagenase solution (Boehringer-
Mannheim, Type P) was injected through the 
duct. The pancreas was loaded into a stainless 
steel digestion chamber and islets were separated 
during a continuous digestion process that lasted 
.30-45 minutes. The main modifications of the 
isolation procedure compared to the previously 
described automated method 13 were the volume 
of the isolation chamber that is now of 500 ml 
with an outlet port diameter of 6mm, and the 
pore size of the screen that was increased from 280 
to 400u. The cooling system as well as the 
heating circuit bypass were eliminated, resulting 
in a simpler isolation apparatus. 1O During the 
recirculation phase (flow rate 85 mllmin) 
intrachamber temperature was increased at a rate 
of 2°Clmin by passage of the solution through a 
stainless steel coil immersed in a water bath 
(50°C). The chamber containing the distended 
pancreas was gently agitated and samples were 
taken every two minutes to monitor digestion. 
After approximately 20-30 minutes of 
recirculation the digestion was Stopped by dilu-
tion (4°C Hanks, 400 ml/min flow rate) and 
cooling. The dilution phase lasted 15-20 min. 
Upon initiation of the dilution phase the cham-
ber was connected to a shaker with oscillation 
amplitude of 10 cm and a variable rate of 0-320 
oscillation/min. Eurocollins solution was used as 
vehicle for the Ficoll powder (Ficoll DL-400, 
Sigma, St. Louis MO). Eurocollins-Ficoll at den-
sities of 1.108, 1.096, 1.037 was used in a three 
layer discontinuous gradient, in which the di-
gested pancreatic tissue was bottom-loaded with 
the 1.1 08 layer. A cell separator (COBE 2991, 
Lakewood, CO) was used for centrifugation of the 
gradients. 21.22 Determination of number, volume 
and purity of the human islets obtained after islet 
separation and purification was performed ac-
cording to recently proposed criteria.21 The final 
preparation was pelleted and suspended in 100 
450 
ml Hank's solution containing 10% human 
albumin and infused into the portal vein catheter 
over 20-30 min. Portal venous pressure was 
measured and in some cases the portal flow was 
assessed by color doppler ultrasonography. In 
patients who received more than one islet prepa-
ration, the portal vein catheter was flushed every 
six hours with 2 ml saline containing heparin 
(100 Vim!). The catheter was removed after 
completion of the last islet infusion. Two patients 
in Group 4 received islets through transcutane-
ous catheterization of the portal vein. 
IMMUNOSUPPRESSIVE MANAGEMENT 
In Group 1, immunosuppression with 
FKS06 began with intravenous doses of 0.07S 
mg/kg every 12 h followed by O.IS mg/kg orally 
every 12 h. The dose was adjusted on clinical 
grounds and by monitoring plasma FKS06 lev-
els. In Group 2, the patients with the autografi:s 
did not receive any immunosuppression. In Group 
3, FKS06 was administered at a dose of 0.1 mgl 
kg IV over 24 h, beginning immediately after 
transplantation. In addition, the patients re-
ceived a 1000 mg IV bolus of methylpred-
nisolone during the operation, followed by a 
maintenance dose of 20 mg prednisolone IV 
daily, until conversion to the oral route. The oral 
dose ofFKS06 was O.IS mg/kg every 12 h (0.3 
mg/kg per day), and 20 mg of prednisone per day 
were given. This dose was reduced and discontin-
ued according to clinical criteria. In Group 4, 
following the intraoperative IV bolus oflOOO mg 
methylprednisolone, a decreasing prednisone dose 
(from 200 to 20 mg/day) was administered over 
6 days. FKS06 was given as in Group 3. When 
possible, the steroid dose was tapered over the 
first several weeks and stopped. Supplementary 
steroids or OKT3 was given if rejection was 
suspected clinically or diagnosed by biopsy. 
PRETRANSPLANT ASSESSMENT OF RECIPIENT 
ISLET FUNCTION 
Basal and stimulated plasma C-peptide lev-
els were measured in all recipients before the 
infusion of the islets. The provocative tests were 
1 mg glucagon IV (Group 1 andOF~ndapustacal 
(6 Kcal/kg)24 or glucagon (Group 3 and 4) chal-
lenges. All patients had absent C-peptide re-
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sponses preoperatively except for one of the pa-
tients with the autograft. 
Posttransplant assessment of donor islet func-
tion: After islet transplantation, plasma glucose 
and C-peptide levels were monitored. An intra-
venous glucose tolerance test (NGT!), was used 
as provocative test of C-peptide secretion in 
patients in Group 1. NGTI was chosen to avoid 
interpretative problems in the evaluation of the 
results since the patients of this group underwent 
significant gastrointestinal resections. In Group 
3 and 4, a Sustacal tolerance test (ST!) was 
selected as provocative test of C-peptide secre-
tion. Glycosylated hemoglobin (HbA1c) was 
measured before and every six weeks after trans-
plantation or when the patients were evaluated in 
follow-up clinics. 
RESULTS 
Islet isolation and purification: Pancreas cold 
ischemia time (CIT) before the islet isolation and 
purification procedure was comparable in the 
three groups, ranging 4-12 hours. In Group 1, 
the 14 human islet preparations that were trans-
planted comprised an average of 392,100 islets, 
representing an average of 279,800 lEg with an 
endocrine volume of approximately 49S Ill. Pu-
riry in islets was 61 % (range 2S-80%). In Group 
3, islet preparation yielded an average of over 
800,000 islets, representing 62S,300 IEq. Aver-
age endocrine volume and puriry in islets were 
1,lOS III and 67% respectively. In Group 4, islet 
isolations resulted in an average of 644,600 islets 
(597,000 lEg) with an endocrine volume of 
1,05 S Ill. The average puriry in islets was 72 %. 
Patients in Group 3 and 4 received a number of 
islets that was significantly higher (p < 0.05) 
compared to the cluster-islet patients of Group 1. 
No significant difference was observed in the 
degree of purity in islets infused in the three 
groups or in the number of islets transplanted in 
Group 3 and 4. 
Patient suroivai: Following our preliminary 
report on cluster-islet allotransplantation," addi-
tional patients died from cancer recurrence 9-20 
months following transplantation, leaving 3 of 
10 patients in Group 1 withfollow-upof24, 21, 
and 8 month. In Group 3, one patient died 36 
hours following combined liver-islet transplan-
tation. The patient had a positive crossmatch 
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(100%) with her liver-islet donor and had pri-
mary hepatic nonfunction because of humoral 
(hypemcute) rejection. A second patient, who 
demonstmted significant islet function for the 
first five postopemtive months, died of hepatitis 
B and sepsis six months after tmnsplantation. In 
Group 4, one patient died of aspimtion pneumo-
nia five days following combined kidney-islet 
tmnsplantation. 
Posttransplant islet function: In Group I, six 
patients did not require insulin for 5 to over 24 
months. The first patient, who received the islet 
allograft on January 10, 1990, is still insulin 
independent over 24 months postopemtively. 
nine months after transplantation the avemge 
value of pre- and postprandial blood glucose 
determinations progressively increased until the 
14th postopemtive month, but has spontane-
ously improved during the last eight months. It 
is of interest that this patient required over 3,000 
and 2,000 units of intmvenous insulin on her 
fourth and fifth postoperative day respectively. 
This is the most insulin we have used in any 
patient in the three groups. Five patients who 
recently died of tumor recurrence did not require 
insulin at the time of recurrence and expired with 
functioning islet grafts. In one patient (No.6) 
who was insulin dependent." the islet function 
progressively improved and insulin treatment 
was discontinued during the third postopemtive 
month. She did not require insulin for five months. 
Insulin treatment was resumed eight months 
after islet allotmnsplantation (2. 5 - 4.1 units/day, 
SQ) for increased fasting plasma glucose levels 
(> 120 mg/dl). The patient was converted to oral 
hypoglycemic agents (glibenclamide 5 mg/day) 
14 months after tmnsplantation since her insulin 
requirement was minimal. She once again does 
not require insulin. One patient (No.8), did not 
require daytime insulin treatment, but was un-
able to discontinue night parenteral nutrition 
(10 units of insulin/night, IV). One patient (No. 
9), did not require insulin until the 10th postop-
erative month, when sudden development of 
symptomatic hyperglycemia in the absence of 
any evidence of liver rejection imposed 
reinstitution of exogenous insulin treatment. 
In Group 2, both patients became insulin-
independent one and four weeks after islet auto-
transplantation and still do not require any exoge-
nous insulin 1 and 10 months fullowing islet graft. 
In Group 3, one patient is alive 16 months 
after tmnsplantation. She had a 100% positive 
cytotoxic crossmatch and a rejection episode 
during the first postopemtive week. Approxi-
mately 80% decrease in her insulin requirement 
was observed over the first six postoperative 
months (from 70 to 15 units of insulin per dayll 
It was evident that glycemic control was ex-
tremely stable compared to preoperative values 
and HbAlc has been within the normal range « 
5.9%). In addition, Sustacal challenge tests two, 
three and six months after tmnsplantation have 
shown progressive improvement of plasma C-
peptide. A delay in C-peptide secretion and 
prolonged elevation during the challenge was 
evident in this patient, as previously reported in 
recipients of cluster islet gmfts.2 The second 
patient, who died six months after tmnsplanta-
tion from hepatitis B and sepsis, also demon-
strated significant islet function. His insulin 
requirement rapidly decreased during the first 
three postoperative weeks. A rejection episode on 
week four imposed a significant increment in the 
daily insulin dose, that never returned to 
prerejection levels. The islets were not com-
pletely rejected as documented by persistence of 
significant basal and stimulated C-peptide levels 
of 0.76 and 1.59 pM respectively (Sustacal chal-
lenge, two months posttmnsplant). 
In Group 4, no patients became insulin 
independent. All patients had at least one rejec-
tion episode in the first postoperative month. 
One patient lost the tmnsplanted kidney due to 
rejection. Of interest in this patient was docu-
mentation ofislet function with basal and stimu-
lated C-peptide ofO. 30 and 0.75 pM respectively, 
after the kidney was completely rejected. The 
patient received a second kidney-islet graft six 
month after the first combined transplant but 
never became insulin independent although re-
ceiving the highest number of islets (> 2,000,000 
IEq) in the study. Basal and stimulated C-pep-
tide was measurable in all cases.6 Two patients 
had 48% and 70% reduction in insulin require-
ments following tmnsplantation. It is of interest 
that basal and stimulated C-peptide levels in 
both cluster-islet and liver-islet groups were 
higher compared to kidney-islet recipients. 6 Dia-
betes was stabilized in all patients, despite they 
all had at least one episode of rejection confirmed 
on biopsy. 
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DISCUSSION 
Several cases of intrahepatic human islet 
allografts have been recently reported 1-4 with 
transient1 or prolonged2-4.6 insulin independence. 
Two patients with type I, insulin-dependent 
diabetes mellituS3,4 received islets from multiple 
donors (four and five pancreata). One of these 
patients I was still insulin-independent 20 months 
after islet allotransplantation. In the present re-
port, prolonged (5 to > 24 months) insulin inde-
pendence was observed in six patients who 
underwent upper abdominal exenteration and 
liver-islet replacement.2•6 Four of them received 
islets from two donors. The first patient of this 
series is still insulin independent over 24 months 
after the islet allograft and received islets from a 
single donor. In contrast, in our experience none 
of the rype I diabetic patients who received either 
a liver-islet or a kidney-islet allograft are insulin 
independent. Although our best result in rype I 
diabetic patients was obtained in a case ofpositive 
crossmatch (l 00%), we currently consider a posi-
tive crossmatch an absolute contraindication to 
human islet allotransplantation. Differences in 
islet isolation and/or purification techniques do 
not explain the inferior results obtained in the 
combined kidney-islet group, since the patients 
in the three groups represent consecutive cases in 
which the same separation and purification pro-
cedure was used for human islet isolation. Pos-
sible explanations forwhich there is experimental 
support include: 1) metabolic dysfunction and/or 
impaired vascular engraftment due to 
longstanding diabetes mellitus;25.26 2) steroid 
treatment that may have a detrimental effect on 
islet engraftment and/or function27 was not used 
in the cluster-islet patients, and was higher in the 
kidney-islet group than in liver-islet recipients; 
3) the immune barrier to islet acceptance might 
be lowered by the presence of a liver from the 
same donor;28 4) inadequacy of the liver as a 
transplant site when islets are allogeneic to the 
liver, possibly for the intrinsic abiliry of the 
hepatic microenvironment (hepatocytes, Kupffer 
cells, endothelium) to generate high levels of 
nitric oxide that is toxic to the islets (unpublished 
observations). 
Based on our data we favor the hypothesis of 
the protective effect of a liver that is syngeneic to 
the transplanted islets, since it could provide a 
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better microenvironment at the islet transplant 
site, e.g., inferior nitric oxide generation for the 
absence of a local allogeneic response. The detri-
mental effect of steroid treatment could have 
played a determinant role as well. Furthermore, 
weight loss was observed during the first 2-3 
postoperative months in all patients receiving a 
cluster-islet graft. The nutritional problem asso-
ciated to upper abdominal exenteration could 
also result in reduced insulin requirement in 
these patients. In addition, the native pancreas is 
removed in these patients who probably have less 
glucagon than rype I diabetic patients. 
In conclusion, our results indicate that 
pancreatectomy-induced diabetes represents a 
favorable setting for long term successful func-
tion of islet cell grafts. Rejection is still a major 
factor limiting the clinical application of islet 
transplantation in patients with rype I diabetes 
mellitus although other factors such as the micro-
environment at the transplant site and steroid 
treatment may contribute to deteriorate islet 
engraftment and/or function. 
REFERENCES 
1. Scharp OW, Lacy PE, Santiago)V et al. Insulin 
independence after islet transplantation into type 
I diabetic patient. Diabetes 1990; 39:515-518. 
2. Tzakis A, Ricordi C, Alejandro R et al. Pancreatic 
islet transplantation after upper abdominal 
exenteration and liver replacement. Lancet 1990; 
336:402-405. 
3. Scharp OW, lacy PE, RicordiCetai. Human islet 
transplantation in patients with type I diabetes. 
Transplant Proc 1989; 21:2744-45. 
4. Warnock GL, Kneteman NM, Ryan E et al. 
Normoglycemia after transplantation of freshly 
isolated and cryopreserved pancreatic islets in type 
I (insulin-dependent) diabetes mellitus. 
Diabetologia 1991; 34:55-58. 
5. Altman)), Cugnenc PH, Tessier C et al. Epiploic 
flap: A new site for islet implantation in man. 
Horm Metab Res (Suppl) 1990; 25: 136-137. 
6. Ricordi C, Tzakis A, Carroll P et al. Human islet 
isolation and allotransplantation in 22 consecutive 
cases. Transplantation 1992; 53:407. 
7. Gray DWR, Morris PJ. Developments in isolated 
pancreatic islet transplantation. Transplantation 
1987; 43:321-331. 
8. Gray DW, Warnock G. Sutton R et al. Successful 
aurotransplantation of isolated islets ofLangerhans 
in the cynomolgus monkey. Br ) Surg 1986; 
73:850. 
9 . Warnock GL, Rajotte R V. Critical mass of purified 
/5 
Islet Transplantation in Diabetes: The Pittsburgh Experience 453 
islets that induce normoglycemia after 
implantation into dogs. Diabetes 1988; 37:467-
470. 
10. Ricordi C, Socci C, Davalli AM et aL Isolation of 
the elusive pig islet. Surgery 1990; 107:688-694. 
11. Alejandro R, Curfield RG, Scheinvold FL et al. 
Natural hisrory of intrahepatic canine islet cell 
aurogtafts. J Clin Invest 1986; 78:1339-1348. 
12. Gray DWR, McShane P, Grant A, Morris PJ. A 
method for isolation of islets of Langer hans from 
the human pancreas. Diabetes 1984; 33:1055-
1061. 
13. Ricordi C, Lacy PE, Finke EH et al. An automated 
method for the isolation of human pancreatic 
islets. Diabetes 1988; 37:413-420. 
14. Scharp OW, Lacy PE, Finke E, Olack BJ. Low-
temperature culture of human islets isolated by 
the distension method and purified with Ficoll or 
Percoll gmdienrs. Surgery 1987; 102:869-879. 
15. Rajotte RV, WarnockGL,Evans M, Dawidson I. 
Isolation of viable islets of Langerhans from 
collagenase-perfused canine and human pancreata. 
Transplant Proc 1987; 19:916. 
16. Alejandro R, Noel J, Latif Z et al. Islet cell 
transplantation in type I diabetes mellitus. 
Tmnsplant Proc 1987; 19:2359-2361. 
17. Starzl TE, Todo S, Tzakis A et al. Abdominal 
organ cluster tmnsplantation for the treatment of 
upper abdominal malignancies. Ann Surg 1989; 
210:374-386. 
18. Tzakis A, Todo S, Stanl TE. Upper abdominal 
exenteration with livet replacement: a modification 
of the cluster procedure. Tmnsplant Proc 1990; 
22:273-74. 
19. Starzl TE, Miller C, Broznick B, Makowka L. An 
improved technique for multipleorganharvesting. 
Surg Gynecol Obstet 1987; 165:343-348. 
20. Ricordi C, Mazzeferrro V, Casavilla A, Scotti C et 
al. Pancreas procurement from multiorgan donors 
for islet transplantation. In Press, Diabetes, 
Nutrition Be Metabolism. 
21. Lake SP, Basset PD, Larkins A et aI. Large-scale 
purification ofhuman isletS utilizing discontinuous 
albumin gradient on IBM 2991 cell separator. 
Diabetes 1989; 38 Supl:143-45. 
22. Alejandro R, Strasser S, Zucker PF, Mintz DH. 
Isolation of pancreatic islets from dogs. 
Semiautomared purification on albumin gradients. 
Tmnsplantation 1990; 50(2):207-210. 
23. Ricordi C, Gray DWR, Hering BJ et aI. Islet 
isolation assessment in man and large animals. 
Acta Diabetol. Lat 1990; 27:185-195. 
24. Goetz Fe. Endocrine assessment of potential 
candidates for pancreas transplantation and 
posttmnsplant monitoring. In: Van Schilfgaarde 
R, Hardy MAeds. Transplantation of the endocrine 
pancreas in diabetes mellitus. New York: Elsevier, 
1988: 333-336. 
25. Hayek A, Lopez AD, Beattie GM. Decrease in the 
number of neonatal islets required for successful 
tmnsplantation by strict metabolic control of 
diabetic rats. Tmnsplantation 1988; 45:940-2. 
26. Hayek A, Lopez AD, Beattie GM. Facrors 
influencing islet transplantation: number, location 
and metabolic control. Transplantation 1990; 
49:224-225. 
27. Kaufman DB, Morel P, Condie R et al. Beneficial 
and detrimental effects of RBC-adsorbed 
antilymphocyte globulin and prednisone on 
purified canine islet aurograft and allograft 
function. Transplantation 1991; 51:37-42. 
28. Moms PJ. Combined liver and pancreatic islet 
tmnsplantation in the rat. Transplantation 1983; 
36:230-231. 
